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ABSTRACT: Cytogenetic hanges in osteochondroma samples were studied by comparative genomic 
hybridization and by chromosome banding. No DNA copy number changes (15 patients) or chromo- 
somal aberrations (9 patients) were observed in any of the patients. © Elsevier Science Inc., 1997 
INTRODUCTION 
Osteochondroma (OC) or osteocartilaginous exostosis is a 
benign cartilaginous tumor with a controversial pathogen- 
esis [1-3]. About 90% of osteochondromas rise in the 
long bones of the limbs in the vicinity of metaphyses. 
Although most of the OCs are sporadic and solitary, multi- 
ple lesions are seen in 2 rare autosomal dominant disor- 
ders: hereditary multiple exostoses syndrome and Langer- 
Giedion syndrome, also called tricho-rhino-phalangeal 
syndrome type II [4]. The OCs of these syndromes are his- 
topathologically indistinguishable from sporadic tumors, 
but are more prone to transform into chondrosarcomas [5]. 
Cytogenetic data on OC is sparse, but a limited number 
of OCs have a deletion in 8q [6, 7]. Patients with heredi- 
tary multiple exostoses syndrome or Langer-Giedion syn- 
drome have constitutional chromosomal rearrangements 
at 8q24, a region linked to hereditary multiple exostoses 
[8, 9]. Linkage studies have identified 3 chromosomal lo- 
cations for the hereditary multiple exostoses syndrome at 
8q24.1 (EXT1), the pericentromeric egion of chromosome 
11 (EXT2), and at 19p11-p13 (EXT3) [9-12]. Loss of het- 
erozygosity has been reported with markers linked to 
EXT1 and EXT2 in both sporadic chondrosarcomas nd 
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chondrosarcomas derived from multiple exostoses [9-13]. 
Thus, it has been suggested that EXT genes have tumor- 
suppressor properties or are indeed tumor-suppressor genes 
[12, 14]. 
CGH offers the possibility to detect DNA sequence copy 
number changes in tumors without specific probes and/or 
previous knowledge of the chromosomal rearrangements 
[15]. In the present study we have adopted CGH to detect 
gains and losses of DNA sequences in 15 osteochondro- 
mas. Chromosome banding analysis also was performed 
on 9 tumors. 
MATERIAL AND METHODS 
The material for CHG comprised 15 primary OC samples 
obtained from 15 patients treated at the Department of 
Orthopaedics and Traumatology, Helsinki University Central 
Hospital (Table 1). The maximum thickness of the cartilag- 
inous cap was measured in perpendicular hematoxylin and 
eosin-stained sections. The tumor specimens, used for the 
DNA extraction according to standard methods, contained 
in general tissue from the cap and the stalk. For tumor 
specimens of patients 1, 2, 4-8, 12, and 13, conventional 
chromosome banding analysis was performed after short- 
term (1-21 days) culture [16]. 
CGH was performed using direct fluorochrome-conju- 
gated DNAs for all samples according to the protocol de- 
scribed elsewhere [15, 17] with minor modifications. 
The hybridizations were analyzed using an Olympus 
fluorescence microscope and the ISIS digital image analy- 
sis system (MetaSystems GmbH, Altlussheim, Germany) 
based on an integrated high-sensitivity monochrome CCD 
camera nd automated CGH analysis oftware. Three-color 
images (red [Texas red] for the reference DNA, green [FITC] 
for the tumor DNA, and blue [DAPI] for the chromosome 
counterstain) were obtained from 12 metaphases from each 
sample. DNA copy number changes were confirmed using 
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Table I Cl inical  characterist ics of the 15 osteochondromas nalyzed by comparat ive genomic  
hybr id izat ion a 
Thickness of the 
Sample number Sex/age b Tumor location Tumor size cartilage cap (cm) 
1 M, 21 Fibula 4.6 x 4.4 x 5.7 0.4 
2 M, 24 Tibia 4.0 x 2.0 x 1.0 0.2 
3 M, 14 Femur NA 0.4 
4 M, 17 Tibia 5.0 x 3.0 x 3.0 0.4 
5 M, 46 Hand 1.3 x 1.0 x 1.0 0.1 
6 M, 15 Femur NA 0.3 
7 M, 17 Femur 1.7 x 0.7 x 0.5 0.9 
8 F, 14 Humerus 8.0 X 2.5 x 2.5 0.7 
9 F, 28 c Scapula NA 0.5 
10 M, 57 c Femur 12.0 X 7.5 x 8.5 2.0 
11 M, 32 Femur 6.0 x 8.0 x 5.0 1.5 
12 M, 19 Femur NA 0.3 
13 M, 28 c Femur 10.0 X 6.0 x 6.0 0.5 
14 M, 31 Scapula 6.0 x 5.0 x 2.5 0.6 
15 M, 37 Tibia NA 0.5 
Abbreviations: F, female; M, male. 
a Tumors 1, 2, 4-8, 12, and 13 had 
b Age in years at diagnosis. 
c Hereditary multiple xostoses. 
normal karyotypes after conventional G-banding analysis. 
a conf idence interval  of 99% with a 1% error probabil i ty.  
In each CGH exper iment,  negat ive (peripheral  b lood DNA 
from normal  donors) and posit ive (tumor DNA wi th  
known copy number  changes) controls were inc luded and 
run s imul taneous ly  wi th  the tumor  samples. 
RESULTS AND DISCUSSION 
The present study is the first report of CGH per formed on 
osteochondromas.  None of the 15 OC samples showed any 
ampl i f icat ions or losses of DNA sequences by CGH. These 
negative CGH f indings are wel l  in l ine wi th  our normal  
results from karyotype analysis. 
Earl ier karyotype analyses by others have demonstrated 
delet ions of the distal part of 8q, but only a very l imited 
number  of tumor cases have been reported so far [6, 7]. In 
the present study no changes were detected at 8q24. As 
both CGH and chromosome banding are rough techniques 
that reveal  only genetic changes of megabases, it still is 
possible that 8q24 or other chromosomal  areas contain loss 
of heterozygosity or gene mutat ions,  such as the frameshift  
mutat ion reported by Ahn  et al. [14]. 
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